Concino Biotech (06185) rose 9.5 percent against the market in early tradingwptpokersite.37%, currently reported at 23wptpokersite.35 Hong Kong dollars, with a turnover of 56.5263 million Hong Kong dollars.
It is reported that in terms of pipeline development, the marketing application for Concino Biotech's 13-valent pneumonia conjugate vaccine PCV13i has been accepted.wptpokersite; Infants with infant component DPT DTcP who have completed Phase III are enrolledwptpokersite; Phase III clinical trials for adsorbed tetanus vaccine have been initiated; Phase I clinical trials for recombinant herpes zoster vaccine (adenovirus vector) have been initiated in Canada; and Phase I clinical trials for recombinant polio vaccine have been initiated in Australia. In addition, the company and AstraZeneca reached a cooperative development agreement on the research and development of mRNA vaccines.